Replies to post #3811 on Marker Therapeutics Inc (MRKR)

[salgovernale69]

Thanks jbem! Is there a more undervalued stock in biotech right now? What am I missing here? This should fairly easily be a $30+M market cap and that's still conservative. $1 by ASCO is quite realistic IMO. Thanks again for the solid DD.

[$Moneypenny$]

Thanks jbeam777. Your picks are just awesome. I'm loaded. Thanks.

[salgovernale69]

Look at the volume on TPIV over the last month. Notice the last few days...then go look at AVXL's volume the month before the run...notice any similarities guys??? TPIV is AVXL to the TEE, with about 1/6th of the float. 100% is a virtual certainty in the short term in my opinion, but given the low float and the absolutely obscene valuation, I wouldn't be shocked to see 0.70 - $1.00 in the near future. The only problem with this stock is that no one knew about it. Well all that is about to change.

[dyp]

Thanks,
Greatly appreciated.

[Canoepaddler]

Picked up a few TPIV based on the quick glance of the due diligence you provided. Larger stake in AVXL, and continue to like what I see there.

[lasers]

Excellent summary.

[JJSeabrook]

HERE'S THE ABSTRACT: http://abstracts.asco.org/156/AbstView_156_148110.html

A phase I trial of the safety and immunogenicity of a multi-epitope folate receptor alpha peptide vaccine used in combination with cyclophosphamide in subjects previously treated for breast or ovarian cancer.

Sub-category:
Vaccines

Category:
Developmental Therapeutics—Immunotherapy

Meeting:
2015 ASCO Annual Meeting

Abstract No:
e14028

Citation:
J Clin Oncol 33:5s, 2015 (suppl; abstr e14028)

Author(s): Pashtoon Murtaza Kasi, Kimberly Kalli, Matthew Stephen Block, Timothy J. Hobday, Travis J. Dockter, Vera J. Suman, Courtney L. Erskine, Daniel W. Visscher, Glynn Wilson, Barath Shreeder, Keith L. Knutson; Mayo School of Graduate Medcl Education, Rochester, MN; Mayo Clinic, Rochester, MN; Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN; TapImmune, Seattle, WA; Cancer Vaccines and Immune Therapies Program, Center for Diseases of Aging, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL; Vaccine and Gene Thrpy Inst of Florida, Port St Lucie, FL

Abstract Disclosures
Abstract:

Background: Folate receptor alpha (FRa) is overexpressed by multiple cancers, including breast and ovarian cancers. Endogenous T-cell immunity to each of five degenerate peptides from FRa (FR30, FR56, FR76, FR113 and FR238) has been demonstrated in both breast and ovarian cancer patients, suggesting the feasibility of targeting FRa via a vaccine approach. Metronomic oral cyclophosphamide (CTX) has been demonstrated to reduce immunosuppressive T regulatory cells (Tregs) and might thereby improve vaccine efficacy. We therefore conducted a Phase I clinical trial testing safety and immunogenicity of a multi-epitope FRa peptide vaccine after 1 cycle of CTX. Methods: Twenty-two patients with breast or ovarian cancer who had undergone standard surgery and adjuvant treatment were treated with 1 cycle of CTX (given days 1-7 and 15-22 of 28). Following this, patients were vaccinated intradermally at 3 sites with a mixture of the 5 FRa peptides on day 1 of a 28 day cycle for a maximum of 6 vaccination cycles. Patients were monitored for toxicity at each visit. Peripheral blood samples were collected for immune monitoring purposes at baseline, at the completion of each cycle of treatment, and at during observation at 3, 6, and 12 months after vaccine completion. The number of Tregs was assessed via flow cytometry, and the number of antigen-specific T cells was assessed via ELIspot. Results: Of 22 patients evaluable for toxicity, one patient developed a grade 3 injection site reaction. Grade 2 reactions were observed in 14 patients and included lymphopenia (5), neutropenia (4), injection site reactions (2), and leukopenia (2). The median frequency of Tregs did not significantly change after CTX use. However, FRa-specific T cell responses were observed in 20 of 21 patients with immune response data. Of these, 16 of 16 patients with observation data had demonstrable T cell responses persisting into the observation phase. Conclusions: Vaccine treatments were associated with mild to moderate toxicity. FRa specific T cell responses were induced in the majority of patients and frequently persisted after completion of vaccine therapy. Clinical trial information: NCT01606241

TPIV ABSTRACT

[ash111]

Great DD. 'jbem777' Institutional Ownership: 55% , but likely more

Empery Asset Master: 4,167,950 Shares
18,772,265 Warrants

http://www.sec.gov/Archives/edgar/data/1094038/000090266415000096/p15-0062sc13g.htm

Brio Capital Master Fund: 5,000,000 Shares
25,000,000 Warrants

Interestingly, there is not a 13G filed for BRIO, but the company’s most recent 10K identifies them as the holder of this many shares and warrants.

Eastern Capital Limited: 5,000,000 Shares
25 Million Warrants

http://www.sec.gov/Archives/edgar/data/1094038/000140840815000026/ecl_tpiv13d.htm

Iroquois Capital Management: 1,945,795 Shares
8,749,975 Warrants

http://www.sec.gov/Archives/edgar/data/1094038/000093041315001217/c80645_sc13g.htm

American Capital Management: 750,000 Shares
37,500,000 Warrants

http://www.sec.gov/Archives/edgar/data/1094038/000114420415016463/v404523_sc13g.htm

Institutional banking on TPIV,and the balance sheet looks great now.

[Investor_cmz]

You need to update your DD. the B series warrants were originally set to expire on 15 July 2015 (before this latest restructuring). You mention in your post they were to expire in June.